January 21, 2021
Boston Scientific (NYSE: BSX) has announced that it has entered into a definitive agreement to acquire Preventice Solutions, Inc., a privately held company, which offers a full portfolio of mobile cardiac health solutions and services, ranging from ambulatory cardiac monitors — including short and long-term Holter monitors — to cardiac event monitors and mobile cardiac telemetry. The transaction consists of an upfront cash payment of US$925 million, and up to an additional US$300 million in a potential commercial milestone payment. Boston Scientific has been an investor in Preventice since 2015 and currently holds an equity stake of approximately 22%, which is expected to result in a net payment of approximately US$720 million upon closing and a milestone payment of up to approximately US$230 million.
Latham & Watkins LLP represents Preventice Solutions, Inc. in the transaction with a corporate team led by Boston partner Hans Brigham, New York partner Nathan Ajiashvili, Orange County partner Shayne Kennedy, and Boston partner Nate Amory, with associates Ross McAloon, Laki Triantafylidis, Thomas Gabay, and Jeffrey Bashara.
Advice was also provided on benefits and compensation matters by Washington, D.C. partner David Della Rocca, with associate Kirk Porter; on tax matters by New York partner Jiyeon Lee-Lim, with associate Alan Kimball; on antitrust matters by Washington, D.C. partner Mandy Reeves; on regulatory matters by Washington, D.C. partner Ben Haas and Bay Area counsel Betty Pang and Heather Deixler, with Washington, D.C. associates Barrett Tenbarge, Alyssa Lattner, and Julie Shin; and on technology transactions matters by Bay Area partner Chris Hazuka, with Boston associate Seth Appiah-Opoku.